At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1 enrolled
Drug / intervention
idarucizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Compassionate Use Program of Idarucizumab for Reversal of the Anticoagulant Effects of Dabigatran in Japanese Patients Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures
In Brief
A Phase 3 clinical trial evaluating idarucizumab for Hemorrhage. Completed, enrolled 1 participant across 1 site.
Detailed Summary
The objective is to collect the safety data of idarucizumab for patients treated with dabigatran who require rapid reversal of the anticoagulant effects of dabigatran in cases of uncontrolled or life-threatening bleeding or when emergency surgery or urgent procedures are required.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemorrhage
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartJul 2016
Primary CompletionSep 2016
TodayJul 2026
First PostedJul 13, 2016
Enrollment StartJul 22, 2016
Primary CompletionSep 16, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.0 years ago
Interventions
idarucizumabdrug